Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.
In the healthcare sector, two major drugmakers, Bristol Myers Squibb (BMY) and Pfizer (PFE), are facing the challenge of patent cliffs and evolving regulatory environments. Both companies have taken steps to navigate the post-pandemic era by acquiring new drug pipelines. Bristol Myers Squibb, known for its focus on serious diseases such as cancer, hematology, and neuroscience, distributes its products globally through wholesalers, specialty pharmacies, and strategic alliances with various pharmaceutical companies.
Pfizer, on the other hand, operates a vast global portfolio encompassing vaccines and primary care. Comparing these industry leaders reveals which option presents a more appealing balance of risk and reward for investors.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
